KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

BACKGROUND: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Osterlund, Emerik, Ristimäki, Ari, Kytölä, Soili, Kuopio, Teijo, Heervä, Eetu, Muhonen, Timo, Halonen, Päivi, Kallio, Raija, Soveri, Leena-Maija, Sundström, Jari, Keinänen, Mauri, Ålgars, Annika, Ristamäki, Raija, Sorbye, Halfdan, Pfeiffer, Per, Nunes, Luís, Salminen, Tapio, Lamminmäki, Annamarja, Mäkinen, Markus J., Sjöblom, Tobias, Isoniemi, Helena, Glimelius, Bengt, Osterlund, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889930/
https://www.ncbi.nlm.nih.gov/pubmed/35251991
http://dx.doi.org/10.3389/fonc.2022.826073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889930/
https://www.ncbi.nlm.nih.gov/pubmed/35251991
http://dx.doi.org/10.3389/fonc.2022.826073

Ejemplares similares